ストックスクリーナーアプリを入手
0.2438
0.08%
-0.0002
アフターアワーズ：
.24
-0.0038
-1.56%
Vistagen Therapeutics Inc (VTGN) 最新ニュース
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
VistaGen Therapeutics (VTGN) Institutional Ownership 2026 - MarketBeat
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics Releases Q1 2027 Financial Results - AlphaStreet
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com India
Vistagen Reports $1.5 Million Revenue and $13.0 Million Quarterly Net Loss - Moomoo
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026 - TradingView
VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data - Stock Titan
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - GlobeNewswire
Press Release: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
VistaGen Granted Nasdaq Extension to Regain Bid Compliance - The Globe and Mail
Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals - Stock Titan
Vistagen (VTGN) Reports Phase 2 Social Anxiety Study Results Ami - GuruFocus
Vistagen reports phase 2 social anxiety trial results - Investing.com
Vistagen's second fasedienol dose showed no new safety findings - Stock Titan
Vistagen reports phase 2 social anxiety trial results By Investing.com - Investing.com Canada
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension - Stock Titan
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - financialcontent.com
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics - TipRanks
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics - finance.yahoo.com
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG - The National Law Review
SRX Global Acquires Stake in Vistagen Therapeutics - Yahoo Finance
SRX Global Inc. Acquires Undisclosed Stake in Vistagen Therapeutics - citybiz
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - The Manila Times
Press Release: SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - Moomoo
$VistaGen Therapeutics (VTGN.US)$ 🫰🏽 see ya later - Moomoo
SRX Global (NYSE American: SRXH) Acquires Stake In Vistagen Therapeutics - Menafn
SRX Global acquires stake in Vistagen Therapeutics - Bitget
Vistagen Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
VTGN FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages V - The National Law Review
VistaGen Therapeutics Appoints Douglas Williamson to Board - The Globe and Mail
Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
Vistagen appoints Douglas Williamson to board of directors By Investing.com - Investing.com Nigeria
Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board - Stock Titan
Vistagen Appoints Douglas J. Williamson to its Board of Directors - GlobeNewswire
Vistagen Therapeutics (VTGN) Holds Steady at $0.24 Amid Tight ConsolidationCall Wall - vinanet.vn
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics, Inc. Revenue Breakdown – BMV:VTGN - TradingView
Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
VTGN|Vistagen Therapeutics Inc|Price:0.226|Chg%:+0.000 - TradingKey
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance
VTGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTGN Stockholders Have Opportunity to Lead Vistagen Therapeutics - The National Law Review
Vistagen Therapeutics (VTGN) Edges Higher as Biotech Sector Nears Key Support LevelAAII Bearish - dars.gov.et
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):